



59th Annual Diagnostic Slide Session 2018

Case 10

M. Adelita Vizcaino M.D.







*Division of Neuropathology and Ophthalmic Pathology,
Johns Hopkins University School of Medicine*

No financial disclosures

Case 10

Clinical summary


- 11-year-old boy
 - One year with right leg length discrepancy
 - Subtle café-au-lait spots
 - X-rays → multiple stress fractures




Case 10



Clinical summary

- Underwent orthopedic surgery with concurrent biopsy of the tibial nerve







1mm





Diagnosis ?





Diagnosis:

**Localized
hypertrophic neuropathy**

Molecular testing

- *KRAS*: c38_40dupGCG found at low level (MAF~16%) by NGS in fresh tissue, cultured Schwann cells, and café-au-lait spots
- No genetic alterations in blood by Sanger Sequencing
- Consistent with a RASopathy with mosaic genetic alteration


Localized hypertrophic neuropathy (LHN)


- Rare Schwann cell proliferation with onion bulb formation
- Most cases are now thought to represent intraneural perineuriomas

RASopathies

- Clinically defined group of overlapping genetic syndromes
- Usually germline mutations in genes encoding components or regulators of the RAS/MAPK pathway
- ~ 1 : 1000 births

Tidyman W, Rauen KA. Curr Genet Med Rep. 2016
Rauen KA. Annu Rev Genomics Hum Genet. 2014
Lissewski et al. Am J Med Genet. 2015










LHN

Differential diagnosis

- Intraneural perineurioma
- Neurofibroma with onion bulb-like formation
- Hereditary neuropathies associated with onion-bulb formation (e.g. Charcot-Marie-Tooth)



S100



EMA



S100

LHN

Perineurioma

**Neurofibroma
w/onion bulb-like**

Conclusions

1. True LHN is a rare disorder that may be associated with activating RAS mutations
2. RASopathies comprise one of the largest groups of familial genetic syndromes
3. Targeted therapies are being developed and may become of practical use to treat a subset of clinical manifestations



Acknowledgments:

Fausto Rodriguez M.D.¹

Verena Staedtke M.D.²

Allan Belzberg, M.D.³

*Division of Neuropathology¹, Departments of Neurology² and
Neurosurgery³,*

Johns Hopkins University School of Medicine

